Mer­ck KGaA looks to boost drug R&D al­liances as the CFO crunch­es the num­bers on de­vel­op­ment costs

Most every­body at the high end of the drug R&D busi­ness has more tri­al work on the ta­ble than they can af­ford to com­plete alone …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.